Saturday, February 18, 2017 9:47:35 AM
The reality is tweed/bedrocan do not have issues and this whole issue is what allowed canopy to land this deal with such a small premium. Mettrum still has patients, products, hemp line & room to expand.
Canopy hasn't begun to scratch the surface of its quarterly revenues, with Germany opening up and getting very medical licensed as well. If the share price is lower in 2 years than what it is today I would be absolutely stunned.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM